Conventional DMARDs 치료에 실패한 류마티스 관절염 환자에서 Biologic DMARDs의 임상적 효과 비교 : 베이지안 네트워크 메타분석

다국어 초록 (Multilingual Abstract)

Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) extend the treatment choices for rheumatoid arthritis patients with insufficient response or intolerance to conventional DMARDs (cDMARDs). These agents have considerable efficacy compared with conventional DMARDs, but only a few head-to-head comparisons among these agents have been performed. The objective of this systematic review and network meta-analysis (NMA) was to compare the relative efficacy of Certolizumab with conventional DMARD to licensed bDMARD with cDMARD therapy for patients who failed to prior cDMARD treatment under the condition of the reimbursement coverage criteria in Korea. Methods: A systematic review was conducted using MEDLINE and Cochrane library. Key endpoints were the American College of Rheumatology (ACR) responses of 20/50/70 at six months. Bayesian outcomes were calculated as median of treatment effect, probability of the best, Odds Ratio (OR) and probability that OR was greater than one. Results: Compared with other bDMARDs, Certolizumab were associated with higher or comparable ACR response rates; in ACR20, the OR (probability of OR>1) was 2.08 (92.6%) for Adalimumab, 1.86 (85.7%) for Etanercept, 1.89 (79.5%) for Golimumab, 2.36 (92.1%) for Infliximab, 1.79 (87.0%) for Abatacept, 1.74 (80.8%) for Rituximab and 1.82 (86.8%) for Tocilizaumab. In ACR50 and ACR70, the ORs did not present significant differences. Conclusion: Certolizaumab with cDMARD was more effective or comparable than other bDMARDs in patients who failed prior cDMARD treatment.

목차 (Table of Contents)

• ABSTRACT
• 연구 방법
• 검색 전략
• 문헌 선정/배제 기준
• 자료추출 및 효과 변수
• 통계 분석: Bayesian network meta-analysis
• 민감도 분석
• 연구결과
• 분석에 포함된 연구
• 베이지안 네트워크 메타분석 결과
• 고찰
• 감사의 말씀
• 참고문헌

참고문헌 (Reference)

1 차훈석, "류마티스관절염 환자에서 항 TNF 제제의 지속성" 대한류마티스학회 18 (18): 231-233, 2011

2 유대현, "류마티스 관절염의 최신 치료 경향" 대한정형외과학회 45 (45): 419-425, 2010

3 Adams R., "Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis" 28 : 477-487, 2010

4 Kremer JM., "Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept : twelvemonth results of a phase iib, double-blind, randomized, placebo-controlled trial" 52 : 2263-2271, 2005

5 van Vollenhoven RF., "Tofacitinib or adalimumab versus placebo in rheumatoid arthritis" 367 : 508-519, 2012

6 Kremer JM., "Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate : results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year" 63 : 609-621, 2011

7 O'Dell JR, "Therapeutic strategies for rheumatoid arthritis" 350 : 2591-2602, 2004

8 Klareskog L., "Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial" 363 : 675-681, 2004

9 Orme ME., "Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis : analysis of American College of Rheumatology criteria scores 20, 50, and 70" 6 : 429-464, 2012

10 Strand V., "Sustained benefit in rheumatoid arthritis following one course of rituximab : improvements in physical function over 2 years" 45 : 1505-1513, 2006

11 Takeuchi T., "Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate" 23 : 226-235, 2013

12 Jang E., "Methods for Bayesian meta-analysis"

13 Genovese MC., "Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs : the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study" 58 : 2968-2980, 2008

14 Maini R., "Infliximab(chimeric antitumour necrosis factor á monoclonal antibody)versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate : a randomised phase III trial" 354 : 1932-1939, 1999

15 Guyot P., "Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom" 39 : 1198-1206, 2012

16 "Health Insurance Review & Assessment Service"

17 Keystone EC., "Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy : the GO-FORWARD Study" 68 : 789-796, 2009

18 Miranda LC., "Finding Rheumatoid Arthritis Impact on Life(FRAIL Study) : economic burden" 37 : 134-142, 2012

19 Combe B., "Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine : a double-blind comparison" 65 : 1357-1362, 2006

20 Emery P., "Efficacy and safety of different doses and retreatment of rituximab : a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate(Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders(SERENE))" 69 : 1629-1635, 2010

21 Smolen J., "Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial" 68 : 797-804, 2009

22 Schiff M., "Efficacy and safety of abatacept or infliximab vs placebo in ATTEST : a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate" 67 : 1096-1103, 2008

23 Kremer JM., "Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis : a randomized trial" 144 : 865-876, 2006

24 Smolen JS., "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis(OPTION study) : a double-blind, placebo-controlled, randomised trial" 371 : 987-997, 2008

25 Smolen JS., "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update" 2013

26 Smolen JS., "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs" 69 : 964-975, 2010

27 Peter JV., "Corticosteroids in the prevention and treatment of acute respiratory distress syndrome(ARDS)in adults : meta-analysis" 336 : 1006-1009, 2008

28 Lu G., "Combination of direct and indirect evidence in mixed treatment comparisons" 23 : 3105-3124, 2004

29 Keystone EC., "Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis" 38 : 855-862, 2011

30 review Ct., "Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis"

31 Keystone E., "Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis : findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study" 58 : 3319-3329, 2008

32 Choy E., "Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX" 51 : 1226-1234, 2012

33 Singh JA., "Biologics for rheumatoid arthritis: an overview of Cochrane reviews" Cd007848-, 2009

34 Jansen JP., "Bayesian meta-analysis of multiple treatment comparisons : an introduction to mixed treatment comparisons" 11 : 956-964, 2008

35 Weinblatt ME., "Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate : the ARMADA trial" 48 : 35-45, 2003

36 Furst DE., "Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis : results of STAR(Safety Trial of Adalimumab in Rheumatoid Arthritis)" 30 : 2563-2571, 2003

37 Weinblatt ME., "A trial of etanercept, a recombinant tumor necrosis factor receptor : Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate" 340 : 253-259, 1999

38 Kim HY., "A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate" 10 : 9-16, 2007